4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, V. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
    Meeting Abstract

    Oaknin, A.; Ang, J. E.; Rha, S. Y.; Yonemori, K.; Kristeleit, R.; Lin, C. C.; Satoh, T.; Garcia, P. E.; Sendur, M. A. N.; Rodríguez, L. M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
    Meeting Abstract

    Tabernero, J.; Yoshino, T.; Kim, T. W.; Yaeger, R.; Desai, J.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T.; Eng, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Ng, K.; Ou, F. S.; Zemla, T.; McCleary, N.; Kalyan, A.; Shusterman, M.; Vijayvergia, N.; Wu, C.; Cohen, S. A.; Pulsipher, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
    Meeting Abstract

    O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
    Pharmacoepidemiology and Drug Safety (2024)

    Fulltext@MSK | Save
  • TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)—directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Shitara, K.; Wainberg, Z. A.; van Cutsem, E.; Janjigian, Y. Y.; Xu, R. H.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save